Literature DB >> 19026705

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.

Joel R Haynes1, Leslie Dokken, James A Wiley, Andrew G Cawthon, John Bigger, Allen G Harmsen, Charles Richardson.   

Abstract

Influenza-pseudotyped Gag virus-like particles (VLPs) were produced via the expression of influenza hemagglutinin (HA), neuraminidase (NA) and the murine leukemia virus Gag product in the baculovirus-insect cell expression system. Hemagglutination specific activities of sucrose gradient-purified VLPs were similar to those of egg-grown influenza viruses but particle morphologies were gamma retrovirus-like in the form of consistent 100nm spheres. Immunization of mice and ferrets demonstrated robust immunogenicity and protection from challenge with no measurable morbidity. Ferret data were striking in that immunization with H5N1 VLPs representing either A/Vietnam/1203/04 or A/Indonesia/5/05 resulted in solid protection against highly pathogenic A/Vietnam/1203/04 challenge with no detectable virus in the upper respiratory tract post-challenge in either group. H1N1 VLP immunization of ferrets resulted in partial protection against H5N1 challenge with markedly accelerated virus clearance from the upper respiratory tract relative to controls. The immunogenicity of influenza-pseudotyped VLPs was not dependent on the adjuvant properties of replication competent contaminating baculovirus. These data demonstrate robust vaccine protection of Gag-based, influenza-pseudotyped VLPs carrying a variety of influenza antigens and suggest applicability toward a number of additional respiratory viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026705     DOI: 10.1016/j.vaccine.2008.11.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Authors:  Jae-Min Song; Jaber Hossain; Dae-Goon Yoo; Aleksandr S Lipatov; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Robert J Hogan; Ruben O Donis; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2010-06-26       Impact factor: 3.616

Review 2.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

Review 3.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

4.  Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals.

Authors:  Jae-Keun Park; Dong-Hun Lee; Seong-Su Yuk; Erdene-Ochir Tseren-Ochir; Jung-Hoon Kwon; Jin-Yong Noh; Byoung-Yoon Kim; Soo-Won Choi; Sang-Moo Kang; Joong-Bok Lee; Seung-Yong Park; In-Soo Choi; Chang-Seon Song
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

5.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

6.  Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Aswani Vunnava; Dae-Goon Yoo; Jae-Min Song; Mark R Prausnitz; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

7.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

8.  Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Alexander V Anstey; Matthew Ivory; Richard W Compans; James C Birchall
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

9.  H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.

Authors:  Xing Cheng; Michael Eisenbraun; Qi Xu; Helen Zhou; Deepali Kulkarni; Kanta Subbarao; George Kemble; Hong Jin
Journal:  PLoS One       Date:  2009-02-11       Impact factor: 3.240

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.